3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
107
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Leukemia
23
Lymphoma
20
Recurrence
16
Burkitt Lymphoma
16
Lymphoma, Mantle-Cell
13
Neoplasms, Plasma Cell
11
Lymphoma, Non-Hodgkin
11
Waldenstrom Macroglobulinemia
9
Lymphoma, Follicular
9
Immunoglobulin Light-chain Amyloidosis
9
Hodgkin Disease
9
Breast Neoplasms
9
Vomiting
8
Neoplasms
8
Nausea
8
Lymphoma, B-Cell, Marginal Zone
8
Lymphoma, Large B-Cell, Diffuse
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma, T-Cell, Cutaneous
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Amyloidosis
6
Leukemia, Myeloid, Acute
5
Smoldering Multiple Myeloma
4
Sezary Syndrome
4
Mycosis Fungoides
4
Lymphoma, Large-Cell, Immunoblastic
4
Lung Neoplasms
4
Blast Crisis
4
Interventions
pembrolizumab
125
Cisplatin
28
Carboplatin
25
lenvatinib
24
Paclitaxel
20
Docetaxel
16
Fluorouracil
13
Pemetrexed
11
Capecitabine
11
Gemcitabine
10
Saline Solution
8
Oxaliplatin
8
epacadostat
6
Leucovorin
5
Irinotecan
5
Cetuximab
5
Albumin-Bound Paclitaxel
5
130-nm albumin-bound paclitaxel
5
olaparib
4
Bevacizumab
4
trifluridine tipiracil drug combination
3
regorafenib
3
enzalutamide
3
durvalumab
3
Nivolumab
3
Etoposide
3
trametinib
2
etoposide phosphate
2
dabrafenib
2
Tretinoin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Calcium Dobesilate
×
Clear all
NCT03834506
2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Completed
1,030 enrolled
24 charts